Neurimmune Holdings AG
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Neurimmune Holdings AG
AstraZeneca Stays Hopeful About Ultomiris Despite Initial Conversion Difficulties
AstraZeneca is touting Ultomiris’ future potential in neurological conditions as it struggles to convert patients from predecessor Soliris in one of its indications.
AstraZeneca Plans To Drug The Undruggable With Scorpion Partnership
The UK major will work with the US biotech to develop up to three precision medicines targeting cancer proteins previously thought undruggable via conventional methods.
Aducanumab Filed In Japan Despite Recent US Setback
Biogen pushes ahead with approval submission in potentially large Japanese market, despite the negative views of a recent advisory committee in the US.
Biogen’s Q2 Highlights Need For Near-Term Successes
Second quarter performance was better than expected, but commercial weaknesses show the need for R&D wins and M&A deals as Tecfidera generics and aducanumab uncertainty weigh on the company.
- Drug Discovery Tools
- Other Names / Subsidiaries
- AL-S Pharma (joint venture)
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.